Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.72 USD | +1.92% | +30.99% | -40.72% |
Apr. 29 | Canaccord Genuity Adjusts Price Target on T2 Biosystems to $3 From $12, Maintains Hold Rating | MT |
Apr. 23 | Top Premarket Decliners | MT |
Financials (USD)
Sales 2024 * | 10.5M | Sales 2025 * | 23.2M | Capitalization | 32.71M |
---|---|---|---|---|---|
Net income 2024 * | -39M | Net income 2025 * | -40M | EV / Sales 2024 * | 3.12 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 1.41 x |
P/E ratio 2024 * |
-1.12
x | P/E ratio 2025 * |
-3.21
x | Employees | 113 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 49.08% |
Latest transcript on T2 Biosystems, Inc.
1 day | +1.92% | ||
1 week | +30.99% | ||
Current month | +10.88% | ||
1 month | +31.45% | ||
3 months | -13.89% | ||
6 months | -31.24% | ||
Current year | -40.72% |
Managers | Title | Age | Since |
---|---|---|---|
John Sperzel
CEO | Chief Executive Officer | 60 | 20-01-07 |
John Sprague
DFI | Director of Finance/CFO | 65 | 18-01-29 |
Roger Smith
CTO | Chief Tech/Sci/R&D Officer | 59 | 13-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
David Elsbree
BRD | Director/Board Member | 76 | 14-06-30 |
Seymour Liebman
BRD | Director/Board Member | 74 | 16-09-20 |
Robin Toft
BRD | Director/Board Member | 63 | 20-06-13 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-03 | 3.72 | +1.92% | 199,459 |
24-05-02 | 3.65 | +21.67% | 260,353 |
24-05-01 | 3 | -10.58% | 507,317 |
24-04-30 | 3.355 | +14.12% | 524,269 |
24-04-29 | 2.94 | +3.52% | 96,324 |
Delayed Quote Nasdaq, May 03, 2024 at 04:30 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-40.72% | 32.71M | |
+7.84% | 218B | |
+7.35% | 184B | |
+13.04% | 135B | |
-1.33% | 62.38B | |
+11.80% | 51.37B | |
+4.81% | 50.9B | |
+0.30% | 40.87B | |
+2.78% | 36.28B | |
+26.14% | 31.88B |
- Stock Market
- Equities
- TTOO Stock